Hematology & oncology:
one pathway, two careers

At a glance

If you were drawn to the detective work of a peripheral smear, to the fast-moving science of cancer therapeutics, and to patients you follow for years through the hardest chapters of their lives, hematology and oncology deserve a serious look. The single most important thing to understand up front is that they are usually not two separate choices. The overwhelming majority of U.S. internists enter both worlds through one combined fellowship, become eligible for two boards, and only then decide how much of each to practice — and those post-fellowship lives differ enough that the decision matrix below is worth reading before anything else. The numbers here summarize the deal.

What it involves

Hematologist-oncologists diagnose and manage disorders of the blood, bone marrow, and lymphatic system, together with solid-organ and hematologic cancers. In practice the work sorts into two broad flavors. Classical (benign) hematology covers non-malignant blood disease — anemias, cytopenias, clotting and bleeding disorders, thrombosis and anticoagulation, hemophilia and von Willebrand disease, and hemoglobinopathies such as sickle cell and thalassemia; it is diagnostic, cognitive, and closely integrated with the laboratory and pathology. Malignant hematology and oncology covers leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes and myeloproliferative neoplasms, stem-cell transplantation, and — for most dual-boarded physicians — the full range of solid tumors. You administer chemotherapy, targeted agents, and immunotherapy; coordinate with surgery, radiation oncology, pathology, and palliative care through multidisciplinary tumor boards; and frequently take part in clinical trials, because the science moves so fast.

The training pathway is the crux of this whole page. After a three-year ACGME-accredited internal medicine residency and ABIM internal medicine certification, the overwhelming majority of U.S. trainees enter a combined three-year hematology/oncology fellowship leading to dual ABIM certification in both medical oncology and hematology⁵. ABIM requires at least 18 months of clinical training within those three years — at least 12 months in neoplastic disease and 6 months in non-malignant hematology — with the remaining time typically for research and scholarship⁶. Fellows usually declare their board intention (both, or just one) around January of the first fellowship year. Adult heme/onc is entered from internal medicine; pediatric hematology-oncology is a separate pathway trained through pediatrics.

A structural note worth knowing early, because it also shapes your maintenance obligations later: ACGME still accredits stand-alone Hematology (24 months) and stand-alone Medical Oncology (24 months) fellowships alongside the combined 36-month program⁷⁸, and ABIM lists Hematology and Medical Oncology as two separate certifications rather than one merged board — so a dual-boarded physician maintains two certificates, each with its own Maintenance of Certification⁶. That is exactly why the combined three-year fellowship is the standard route for anyone who wants to be eligible for both: it is the doorway that keeps the most doors open afterward.

A day in the life

A community hematologist-oncologist's day is built around the outpatient clinic and the infusion suite. The morning is a mix of new-consult visits — a newly diagnosed breast cancer to stage and plan, an abnormal CBC to work up, a clotting-disorder referral — and follow-ups on patients mid-treatment whose counts, symptoms, and scans you review. Between visits you sign off on infusion-center orders and manage the day's toxicities: a neutropenic fever to admit, nausea to control, an immunotherapy side effect to sort out. Midday is often a multidisciplinary tumor board, where you present cases alongside pathology, radiology, surgery, and radiation oncology. The afternoon returns to clinic and the inbox — results to interpret, prior authorizations to fight, families to call. Threaded through all of it are the serious-illness conversations that define the field: delivering a diagnosis, discussing prognosis honestly, and aligning treatment with what a patient actually wants. It is cognitive, longitudinal, and emotionally weighty work — and it looks markedly different on an inpatient leukemia or transplant service, where acuity and after-hours load rise sharply.

One pathway, two careers

Here is the reality residents most often miss. When someone says “I want to do hematology” or “I want to do oncology,” they are usually describing the same fellowship ecosystem. Stand-alone hematology and stand-alone medical oncology fellowships exist, but applicants and programs concentrate overwhelmingly in the combined pathway. In the 2026 appointment-year Match, combined Hematology and Oncology offered 809 certified positions; NRMP broke out no stand-alone hematology track at all, and the only separate oncology listing was a single small program¹. Practically, most people who want a classical-hematology career train through the combined fellowship and then concentrate their practice on benign disease. The divergence happens after training, and the tracks differ enough that it is worth seeing them side by side before you read further.

Two axes drive the divergence. The first is heme versus onc: among the minority who single-board rather than dual-board, oncology-only is roughly ten times more common than hematology-only, with single-boarded hematologists disproportionately at teaching hospitals⁹. The second is academic versus community: classical/benign hematology, stem-cell transplant, and physician-scientist careers cluster in academic and tertiary centers; broad general oncology and community cancer practice dominate outside them. Most community physicians simply do both; the pure identities live closer to referral centers. Specialization also keeps evolving after fellowship — a generalist can narrow toward a disease group over time, or a solid-tumor oncologist can add cellular therapy at a center that offers it.

The takeaway for planning: if you want the broadest employability and the strongest pay ceiling, the combined fellowship followed by a general or solid-tumor-heavy career is the default. If you already know you are drawn to blood disease itself — coagulation, sickle cell, marrow failure, the smear and the flow cytometer — you can build that career too, but expect it to be narrower, more academic, and more institution-dependent. Either way, you almost certainly start in the same fellowship.

Competitiveness

Hematology/oncology is among the most competitive internal medicine subspecialties, and it has grown steadily more so. In the 2026 appointment-year Match, the combined track offered 809 certified positions across 212 programs and filled 805 — a 99.5% fill rate; on the applicant side it was much tighter, with about 1,164 applicants preferring it, 803 (69.0%) matched, and 341 (29.3%) unmatched — the classic signature of a genuinely competitive fellowship, roughly 1.4 applicants per position¹. The longer trend is expansion and intensifying competition: programs grew from 130 (2014) to 230 (2025) and positions from 517 to 773, with fill reaching about 99.7% and the unmatched rate climbing to about 25%, even as the matched non-US-IMG share drifted from 33.5% to 27.1%¹¹.

An applicant-development timeline. Heme/onc rewards early, sustained preparation:

1. PGY-1: get onto heme and onc rotations early, find a faculty mentor, and start one scholarly project; strong internal-medicine performance is the foundation.
2. PGY-2: convert the project into tangible output — abstracts and posters at ASH, ASCO, SOHO, or AACR; complete Step 3; secure advocacy-grade letters, ideally one from a hematologist or oncologist who knows you well.
3. PGY-3 (application year): apply broadly and align your 5 gold / 15 silver signals with genuine fit and your visa posture; many competitive programs effectively screen out non-signalers¹³.

What does a competitive applicant look like? Strong IM performance, genuine research output, meaningful clinical exposure, and strong letters. The research-intensive lanes skew hardest toward U.S.-MD applicants. If you do not match on the first attempt, the familiar paths forward apply — a chief-residency year, a hospitalist or dedicated research year, and reapplication — and unaccredited “pre-fellowship” roles that promise a match should be vetted hard for track record and fair pay.

Skills & personality

This field asks for both the head and the heart, and it is honest to say you need both. On the cognitive side, hematology is famously a detective specialty: interpreting a peripheral smear, integrating coagulation studies, flow cytometry, and marrow findings, and building a differential from subtle clues is central work, especially in classical hematology. Oncology demands comfort with probability and uncertainty — treatment decisions hinge on statistics, evolving evidence, and shifting molecular data — plus the detail orientation to dose therapy precisely and manage toxicity vigilantly. Across both, the knowledge base turns over faster than almost any other specialty, so voracious, lifelong learning is not optional; people who prefer a stable, finite body of knowledge tend to struggle.

On the human side, this is a longitudinal-relationship field. You follow patients for months to years, through remission, recurrence, and sometimes death. Breaking bad news, running goals-of-care and end-of-life conversations, and sustaining realistic hope are daily tasks, and they require real communication skill and emotional resilience. Notably, oncologists themselves cite these relationships as a top source of meaning — in the ASCO well-being data, 63% named “speaking with and advising patients” as a leading source of joy¹⁴. Care is also deeply collaborative: tumor boards, pathology, radiation oncology, surgery, pharmacists, and advanced-practice providers are constant partners.

Who tends to be unhappy? Physicians who want a heavily procedural identity or high-throughput, one-and-done problem-solving; those who find repeated exposure to grief and death corrosive rather than meaningful; those uncomfortable holding prognostic ambiguity; and those worn down by the heavy documentation, prior-authorization, and RVU-driven productivity pressure that dominate modern oncology. If in residency you found yourself reading up on cancer therapeutics or lingering over a confusing CBC — and were also comfortable at the bedside during a serious-illness conversation — that is a strong signal this path could fit.

Lifestyle & burnout

The lifestyle is moderate and, more than almost anything else, setting-dependent. Reported hours vary by survey and definition: Medscape put the average oncologist work week near 52 hours, ASCO's 2023 well-being survey found a median closer to 60, and crowdsourced community data land around 49 — so the honest range is roughly 49–60 hours, with partners and owners often at the top of it¹⁴¹⁵. The core of the week is outpatient clinic plus infusion-center oversight and tumor boards; the intensity comes from patient complexity and care coordination rather than shift count. Call is generally lighter than in GI or cardiology and rarely procedure-heavy overnight, but the after-hours burden is real — symptom calls, neutropenic fevers, and management of admitted patients. The spread within the field is enormous: classical/benign hematology and outpatient community oncology are among the more controllable niches, while malignant hematology, leukemia service, and stem-cell transplant carry the heaviest load.

Burnout is a genuine and rising concern, and it is largely a systemic problem, not a personal failing. ASCO's professional well-being survey found burnout among practicing U.S. oncologists rose from 45% in 2013 to 59% in 2023; high emotional exhaustion climbed from 38% to 57% and depersonalization from 25% to 34%, and fewer than 25% were satisfied with work-life integration in 2023. It ran higher among those under 50, those with caregiving responsibilities, and those working the longest weeks¹⁴. A related study linked purely RVU-based compensation and female gender to higher burnout¹⁶. The most-cited stressors are staffing shortages and EHR/administrative load — not, notably, the emotional content of the work itself.

Compensation & infusion economics

Heme/onc sits in the upper-middle tier of physician pay — consistently a top-ten earning specialty, though not at the very top of the procedural fields. Two features complicate any single number: surveys categorize “hematology” and “oncology” differently, and they mix averages with medians and different panels. Read the table as a range, not a promise.

The lower survey-median figures and the higher self-reported ones differ mostly on methodology — average versus median, and who answers^2171815. The heme-versus-onc gap is real and instructive: Doximity separately listed oncology about $502,465 and hematology about $421,482, echoing the structural point that infusion-heavy oncology monetizes better than benign hematology³. Notably, oncology pay fell slightly in the most recent Medscape cycle while the broader market rose — a reminder that reimbursement pressure is real.

What drives the paycheck is productivity and drug economics rather than a large procedural book. Community oncology has a distinctive engine: infusion / “buy-and-bill” drug revenue, where practices purchase expensive infused chemotherapy, immunotherapy, and biologics and are reimbursed at a margin. Academic positions commonly trade income for protected research and teaching time; MGMA data put physician-owned salaried pay near $471,855 versus hospital/health-system near $533,047, with partner/owner equity models higher still¹⁷.

Rural and underserved markets frequently add premiums plus loan forgiveness, and there is a real career arc: starting offers have risen (AMN/Merritt Hawkins about $490,000), and earnings generally build toward well over $600,000 with seniority or partnership¹⁸.

Intellectual scope

Few fields evolve as fast, and that pace is the field's signature intellectual draw. The day-to-day is overwhelmingly cognitive: interpreting pathology and molecular data, selecting and sequencing therapy, managing toxicity, and having complex conversations. For the hematology-minded, the lab-integrated core — smear and marrow interpretation, coagulation testing, flow cytometry, and close work with hematopathology — is its own deep intellectual reward. Therapeutic innovation is reshaping practice in real time: precision oncology matches targeted agents to actionable alterations through molecular tumor boards; immune checkpoint inhibitors have transformed treatment across many tumor types; antibody-drug conjugates are expanding fast; and on the hematology side, CAR-T cellular therapy and bispecific antibodies have changed the management of relapsed or refractory myeloma, lymphoma, and leukemia, while gene therapy has arrived for sickle cell disease and hemophilia.

It is honest, though, to name the burden that comes with the excitement. The pace cuts both ways: guidelines, approvals, and biomarkers change constantly, so staying current is a permanent obligation rather than a phase, and you will often practice at the edge of evidence uncertainty, making decisions on immature or conflicting data. The new modalities bring serious toxicity-management demands — cytokine-release syndrome and neurotoxicity from cellular therapies require specialized monitoring²⁰. And the therapies are extraordinarily expensive, which surfaces real access inequity and genuine moral distress: deciding how hard to push a marginally beneficial, six-figure regimen, or watching coverage and geography determine who can receive a curative cell therapy, is part of the emotional weight of the field, not a footnote to it. Clinical trials are woven into everyday practice at academic and many community sites, and that is a privilege — but the whole enterprise asks you to hold hope and honesty at the same time.

Pathways & career arc

Three practice models dominate. Academic centers trade lower cash compensation for protected research and teaching time, complex referral cases, trial access, and subspecialty focus; this is the home of most classical-hematology, transplant, and physician-scientist careers. Private practice and community oncology offer the highest income potential through ownership, ancillary and infusion revenue, and a broad generalist scope, at the cost of higher patient volumes. Hospital- and health-system-employed roles offer stable salaries with wRVU incentives and are a growing share of the market. One structural trend to know: community oncology has consolidated heavily, with practices increasingly acquired by health systems or rolled up by private-equity-backed platforms¹⁹ — so new graduates find fewer traditional independent-partnership tracks and more employed or PE-affiliated roles. Non-clinical and hybrid options are unusually plentiful here: the biopharmaceutical industry hires heme/onc physicians heavily²¹, alongside telehealth, informatics, administration and physician leadership, and lucrative locum tenens.

The demand picture is strong and structurally worsening, which is good news for job security. ASCO's 2025 workforce report found the number of oncologists rose from 12,267 in 2014 to 14,547 in 2024, yet density per 100,000 people aged 55+ fell from 15.9 to 14.9; 38 states had fewer oncologists per capita than a decade earlier; 68% of Americans aged 55+ live in counties where coverage is “at risk” from impending retirements; and by 2037, non-metropolitan areas are projected to meet only about 29% of demand versus about 102% in metros⁴²². Against that flat-to-shrinking supply, the American Cancer Society projected more than 2.1 million new U.S. cancer cases and 626,140 deaths in 2026²³. The classical-hematology gap is even more specific: only about 5% of adult hematologist-oncologists at NCI-designated cancer centers are classical hematologists²⁴. Net: excellent job security overall, and exceptional leverage for candidates willing to practice classical heme and/or in underserved geographies.

The career arc, honestly. Heme/onc is a cognitive, largely non-procedural field, which makes it durable: there is no physical clock running out on your hands, and the work scales into part-time, telemedicine, and hybrid arrangements. Many physicians narrow toward a disease group over time, add cellular therapy at a center that offers it, or move toward tumor-board leadership, clinical-trial oversight, medical direction, or industry. The emotional load is the real sustainability variable, not the physical one — which is why the job-quality factors above (staffing, coverage, peer support) matter as much for a thirty-year career as the starting salary does. A second, non-clinical domain (pharma, devices, trial leadership) is unusually accessible in this field, and worth cultivating early.

Choosing a fellowship & first job

Heme/onc asks you to choose twice: first a fellowship, then a first attending job. The through-line is the same both times: decide what matters for your direction, evaluate the program or group against it, and negotiate the terms.

Choosing the fellowship. Weigh clinical breadth and the balance of heme versus onc exposure, research support if you want an academic or physician-scientist path, access to cellular therapy and trials, mentorship and where the program's graduates actually land, geography, and — for IMGs — documented visa sponsorship (below). If you are drawn to classical hematology specifically, look hard at whether a program genuinely supports a benign-heme concentration.

Choosing the first job. Normalize competing offers to the same terms and get the details in writing:

• The clinical model: the heme/onc mix and disease scope, expected census and new-patient volume, inpatient versus outpatient weighting, call structure, and the team staffing and inbox support that determine day-to-day sustainability (see the job-quality checklist above).
• The economics and its governance: base versus wRVU (and the conversion factor), any infusion or ancillary participation, and — critically — how regimen selection is governed so drug economics do not bend clinical judgment.
• The contract: non-compete scope, without-cause termination, malpractice and tail, protected/academic time if promised, and who actually employs you (independent group, hospital, PE platform, or academic department), which shapes autonomy and what happens if the group is acquired.

IMG considerations

International medical graduates are not a footnote in this field — they are a cornerstone of the workforce. Roughly one-third of practicing medical oncologists are IMGs (37.1% as of 2019), and IMGs make up close to half of current heme/onc fellows²⁵. In the 2026 appointment-year matched cohort, non-U.S. IMGs were 28.8% and U.S.-citizen IMGs 7.6% — more than a third of matched fellows¹. There is a real seat at this table for you. (Two companion analyses take up the wider questions: whether international graduates take U.S. graduates' spots, and the H-1B for physicians in training; practical planning lives on the IMG guide.)

The bar is genuinely higher, and you should plan around it. The 15-year analysis found IMG match rates around 50%, versus about 83% for U.S. MDs, and program-director surveys have flagged non-U.S.-citizen IMGs among the most disadvantaged applicant groups — even as IMG applicants tend to be markedly more research-productive than domestic peers¹²²⁶. The playbook is straightforward: publish early and often in hematology/oncology, secure strong U.S. clinical experience and letters from faculty who know the fellowship match, and use your signals deliberately on programs whose visa posture fits yours.

Visa strategy deserves as much thought as your CV, and it must be verified program by program. J-1 (ECFMG-sponsored) is the most common and most widely accepted training visa; it is administratively easier for programs but carries the two-year home-country return requirement, typically navigated later through a Conrad 30 or similar waiver tied to underserved-area service²⁷²⁸. H-1B offers a cleaner path to permanent residency but is sponsored by fewer programs — many describe sponsoring it only rarely, because the institution bears the cost and paperwork; academically affiliated nonprofits can be cap-exempt²⁹. Two wrinkles matter for career shape: J-1 waiver jobs for subspecialists are often scarce in academia and concentrated in underserved/rural areas, which can steer early-career IMG oncologists toward community practice, and J-1 holders are generally ineligible for NIH grants, complicating an academic research track. One survey found 74% of heme/onc fellows consider visa status a major factor in their career choices²⁵.

The good news is that the field's rural and underserved shortage aligns well with waiver obligations — the same geography that needs oncologists most is where a J-1 waiver can be satisfied, often with premium pay. Map this out before you rank residency programs, not after fellowship interviews; this is exactly the kind of multi-year planning a mentor is for.

Bottom line

Consider this path if you… love diagnostic, lab-integrated reasoning (smears, marrows, coagulation, flow cytometry) and/or complex, probabilistic cancer medicine; want deep, longitudinal relationships with patients; are energized rather than exhausted by a knowledge base that changes every year; can carry the emotional weight of serious and terminal illness with resilience; and value strong job security, broad geographic and non-clinical options, and solid (if no longer fast-growing) compensation. If you are drawn specifically to blood disease, classical/benign hematology offers a more predictable lifestyle, intense intellectual reward, and a documented workforce gap that translates directly into leverage — mostly in academic and larger-center settings.

It may not fit if you… want a procedure-heavy day or clean, one-and-done problems; find repeated exposure to death, grief, and goals-of-care conversations depleting rather than meaningful; dislike heavy EHR, documentation, and prior-authorization burden; are seeking the shortest possible training or the very highest earning ceiling (the top earnings favor infusion-heavy oncology, not classical hematology); or, as an IMG, cannot yet build the research and U.S.-clinical profile the field rewards. Burnout is real, rising, and largely systemic, so screen the job's staffing and coverage as carefully as you assess your own stamina.

A last mentor's note. Whichever way you lean, remember the central fact of this page: you almost certainly enter both worlds through one door, and decide how to divide them afterward. Choose it because the reasoning and the relationships genuinely draw you — then find a hematologist-oncologist whose practice looks like the life you want, spend real time watching it, and, when the offers come, evaluate the job — its staffing, its coverage, its ethics — as carefully as you chose the field.

References

1. National Resident Matching Program. (2025). Results and data: Specialties Matching Service — Match Results Statistics, Medicine and Pediatric Specialties, 2026 appointment year. https://www.nrmp.org/match-data/ Combined Hematology and Oncology track: 809 certified positions, 805 filled (99.5%); of about 1,164 applicants preferring it, 803 matched (69.0%) and 341 (29.3%) did not match. Matched cohort: 53.0% US MD, 10.6% DO, 7.6% US-citizen IMG, 28.8% non-US IMG. ↩₁ ↩₂ ↩₃ ↩₄
2. Medscape. (2025, 2026). Oncologist compensation reports (2024 and 2025 earnings). Self-reported survey; subscription access required, not reproduced here. Oncology/hematology average about $472,000 (2024 data) and about $464,000 (2025 data), roughly a 2% year-over-year decline while the broader physician market rose. ↩₁ ↩₂
3. Doximity. (2025). Physician compensation report 2025 (2024 data). https://www.doximity.com/reports/physician-compensation-report/2025 Self-reported/modeled survey. Oncology about $502,465; hematology (separate category) about $421,482. ↩₁ ↩₂
4. American Society of Clinical Oncology. (2025). The state of the hematology and medical oncologist workforce. JCO Oncology Practice. https://pubmed.ncbi.nlm.nih.gov/41056511/ Oncologists rose from 12,267 (2014) to 14,547 (2024), yet density per 100,000 aged 55+ fell from 15.9 to 14.9; 38 states had fewer oncologists per capita than in 2014; 68% of Americans aged 55+ live in "at-risk" counties; only 4% of oncologists practice in high-cancer-mortality counties. By 2037, non-metro areas are projected to meet about 29% of demand versus about 102% in metros. ↩₁ ↩₂
5. Accreditation Council for Graduate Medical Education. (2026). Program requirements for graduate medical education in hematology and medical oncology. https://www.acgme.org/globalassets/pfassets/programrequirements/2026-prs/155_hematologymedicaloncology_2026.pdf Combined 36-month fellowship — the standard route to eligibility for both boards. ↩
6. American Board of Internal Medicine. (n.d.). Subspecialty certification eligibility and policies (hematology; medical oncology). https://www.abim.org/certification/becoming-certified-in-a-subspecialty/confirm-your-eligibility/ Hematology and medical oncology are two separate ABIM certifications. The combined pathway requires at least 18 months of clinical training within three years — at least 12 months in neoplastic disease and 6 in non-malignant hematology — and each certificate carries its own Maintenance of Certification. ↩₁ ↩₂
7. Accreditation Council for Graduate Medical Education. (2026). Program requirements for graduate medical education in hematology. https://www.acgme.org/globalassets/pfassets/programrequirements/2026-prs/145_hematology_2026.pdf Stand-alone 24-month hematology track. ↩
8. Accreditation Council for Graduate Medical Education. (2026). Program requirements for graduate medical education in medical oncology. https://www.acgme.org/globalassets/pfassets/programrequirements/2026-prs/147_medicaloncology_2026.pdf Stand-alone 24-month medical oncology track. ↩
9. Single- versus dual-boarding among Medicare-billing hematologist-oncologists. (2025). Journal of Clinical Oncology. https://ascopubs.org/journal/jco Single-boarding in oncology was roughly ten times more common than in hematology; single-boarded hematologists disproportionately worked at teaching hospitals. ↩
10. American Society of Hematology / George Washington University. (2019). Hematology workforce study. https://www.hematology.org/ Survey of about 2,500 hematologists: 46% reported a shortage of classical-hematology specialists versus 31% for blood-cancer specialists. ASH responded with its Hematology-Focused Fellowship Training Program (10 tracks at nine institutions), aiming to produce 50 new academic classical hematologists by 2030. ↩
11. Mustaqeem, R., & Mulla, Z. (2025). Trends in the hematology/oncology fellowship match. Blood. https://ashpublications.org/blood NRMP-data analysis: programs grew from 130 (2014) to 230 (2025) and positions from 517 to 773; fill reached about 99.7% and the unmatched rate climbed to about 25%; the matched share of non-US IMGs drifted from 33.5% to 27.1%. ↩
12. Fifteen-year analysis of hematology/oncology fellowship match rates by graduate type, 2009–2023. (2024). JCO Oncology Practice. https://ascopubs.org/journal/op Match rates of roughly 83% for US MDs, about 60% for US DOs, and about 50% for IMGs. ↩₁ ↩₂
13. Association of American Medical Colleges. (2025). ERAS fellowship program signaling. https://students-residents.aamc.org/applying-fellowships-eras/eras-fellowship-program-signaling The combined hematology/oncology track uses a two-tier system of 5 gold and 15 silver signals per applicant, allocated at the institution level. ↩
14. Professional well-being among US oncologists, 2013 vs 2023. (2025). JCO Oncology Advances. https://pmc.ncbi.nlm.nih.gov/articles/PMC11789616/ ASCO well-being survey: burnout rose from 45% (2013) to 59% (2023); high emotional exhaustion 38%→57%, depersonalization 25%→34%; fewer than 25% satisfied with work-life integration in 2023; higher among those under 50, caregivers, and the longest-hour cohort. 63% named speaking with and advising patients as a leading source of joy. ↩₁ ↩₂ ↩₃
15. Marit Health. (2026). Hematologist-oncologist salary and hours (community-sourced). https://www.marithealth.com/ Crowdsourced, self-reported; directional only, not a representative survey. Average about $573,860 total ($498,810 academic, $607,957 non-academic); reported hours about 49/week. ↩₁ ↩₂
16. Compensation model, gender, and oncologist burnout. (2023). Blood Advances. https://ashpublications.org/bloodadvances Linked purely RVU-based compensation and female gender to higher burnout. ↩
17. MGMA. (2023). DataDive provider compensation (2022 data). Subscription-gated, not reproduced here. National median total compensation about $516,017; physician-owned salaried about $471,855 versus hospital/health-system about $533,047. ↩₁ ↩₂
18. AMN Healthcare / Merritt Hawkins. (2025). Review of physician and advanced practitioner recruiting incentives. https://www.amnhealthcare.com/amn-insights/physician/surveys/ Average starting offer about $490,000 (range about $246,000–$600,000); hematology/oncology among its most-requested specialties. Recruiting-incentive data reflect starting offers, not experienced-physician pay. ↩₁ ↩₂
19. Private-equity acquisition of oncology practices, 2003–2022. (2023). JAMA Internal Medicine. https://jamanetwork.com/journals/jamainternalmedicine Documented 724 oncology clinics becoming private-equity-affiliated over 2003–2022. ↩₁ ↩₂
20. Toxicities of CAR-T and bispecific antibody therapy. (2025). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764151/ Reviews cytokine-release syndrome and the specialized monitoring that cellular therapies require. ↩
21. Biopharmaceutical career opportunities in hematology-oncology. (2017). Blood Cancer Journal. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637109/ Documents the unusually high volume of industry roles available to heme/onc physicians. ↩
22. HRSA National Center for Health Workforce Analysis. (2025). Physician workforce projections, 2023–2038. https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/data-research/physicians-projections-factsheet.pdf Metropolitan versus non-metropolitan demand projections. Projection, not a guarantee. ↩
23. American Cancer Society. (2026). Cancer facts & figures 2026. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html Projected more than 2.1 million new US cancer cases and 626,140 deaths in 2026. ↩
24. Classical hematologists at NCI-designated cancer centers. (2024). Blood. https://ashpublications.org/blood Only about 5% of adult hematologist-oncologists at NCI-designated cancer centers are classical hematologists. ↩
25. ASCO IMG Community of Practice. (2024/2025). Supporting international medical graduates in hematology and oncology. JCO Oncology Practice. https://pubmed.ncbi.nlm.nih.gov/39374449/ Roughly one-third of practicing medical oncologists are IMGs (37.1% as of 2019); IMGs are close to half of current heme/onc fellows; one survey found 74% of fellows consider visa status a major factor in career choices. ↩₁ ↩₂
26. Bias against international medical graduates in hematology/oncology fellowship recruitment. (2022). JCO Oncology Practice. https://pubmed.ncbi.nlm.nih.gov/36108253/ Program-director survey flagging non-US-citizen IMGs among the most disadvantaged applicant groups; IMG applicants tend to be markedly more research-productive than domestic peers. ↩
27. Educational Commission for Foreign Medical Graduates. (n.d.). Exchange Visitor Sponsorship Program (J-1): General information. https://www.ecfmg.org/evsp/applying-general.html ↩
28. U.S. Citizenship and Immigration Services. (n.d.). Conrad 30 Waiver Program. https://www.uscis.gov/working-in-the-united-states/students-and-exchange-visitors/conrad-30-waiver-program ↩
29. Reported visa acceptance and sponsorship in internal medicine residency. (2022). Journal of Graduate Medical Education. https://pmc.ncbi.nlm.nih.gov/articles/PMC9765918/ J-1 versus H-1B program policies; many programs sponsor H-1B only rarely because the institution bears the cost and paperwork. ↩
30. Restriction on Entry of Certain Nonimmigrant Workers, Proclamation No. 10973. (2025, September 24). Federal Register. https://www.federalregister.gov/documents/2025/09/24/2025-18601/restriction-on-entry-of-certain-nonimmigrant-workers Signed September 19, 2025; effective September 21, 2025. Imposes a $100,000 payment requirement on certain new H-1B petitions for beneficiaries outside the United States, with national-interest exemptions and a twelve-month sunset absent extension. ↩
31. U.S. Citizenship and Immigration Services. (2025). H-1B: Frequently asked questions on the September 2025 proclamation. https://www.uscis.gov/newsroom/alerts/h-1b-faq USCIS guidance that the payment requirement applies to new petitions for beneficiaries outside the United States without a valid H-1B visa, and does not reach previously issued visas, earlier-filed petitions, renewals, or change-of-status, amendment, and extension petitions for people already in the country. ↩
32. State of California v. Mullin, No. 1:25-cv-13829-LTS (D. Mass. June 8, 2026) (Sorokin, J.), appeal docketed, No. 26-01699 (1st Cir. 2026). https://www.fragomen.com/insights/united-states-district-court-temporarily-stays-order-vacating-dollar100000-h-1b-fee.html The district court vacated the payment requirement on June 8, 2026 as an unlawful tax and Administrative Procedure Act violation, then temporarily stayed its own order on June 12, 2026 pending appeal; the government appealed to the First Circuit. The requirement therefore remains operational for affected petitions at this writing. A fast-moving matter — verify current status before relying. ↩

Figures here are survey-, model-, and projection-based and shift year to year; compensation figures are self-reported survey and crowdsourced estimates that differ by method and are read only directionally, and several are subscription-gated; Match statistics, signaling rules, workforce projections, and the immigration landscape all move. Verify against the primary source before relying on any single figure for a career, contract, or immigration decision. This page is educational and is not career, financial, immigration, or legal advice.